Novel injectable hydrogel for treating bronchopleural fistula

Abstract

The invention discloses novel injectable hydrogel for treating bronchopleural fistula. The synthetic method of the novel injectable hydrogel for treating the bronchopleural fistula comprises the following steps: A. synthesis of vitamin K3-carnosine (VKCP): menadione and thiolactic acid are respectively taken and placed in a double-necked round-bottom flask, then methyl alcohol is added in the flask, a mercapto-michael addition reaction is carried out for 2 hours under an ice-bath condition for overnight at room temperature, so that a new sulfo-menadione is obtained. The novel injectable hydrogel for treating the bronchopleural fistula can promote cell proliferation, and the cell activity after the proliferation is 95% or above, is free of cytotoxicity and high in safety, at the same time,VCFP has a high antibacterial property, and a relatively sterile environment can be created by killing harmful bacteria around the fistulae to accelerate tissue repair, furthermore, the hydrogel has characteristics of targeted delivery, mechanical stability, and sustained release, can facilitate the sustained release of a growth factor, promote proliferation and differentiation of the cell and tissue regeneration, strengthen the mechanical strength of new tissue, and prolong sustained time of the effect.

Description

technical field [0001] The invention relates to the technical field of novel biomaterials, in particular to a novel injectable hydrogel for treating bronchopleural fistula. Background technique [0002] Bronchopleural fistula is a pathological channel formed between the trachea, bronchus at all levels, or alveoli and the pleural cavity. The morbidity after lobectomy is 0.5% to 3%, the morbidity after pneumonectomy is 2% to 20%, and the mortality rate is as high as 18% to 50%. It is one of the most serious complications of thoracic surgery. In addition, A variety of respiratory diseases can lead to the occurrence of BPF, such as pulmonary tissue degeneration, necrosis, and perforation caused by pulmonary infections such as tuberculosis and fungi, tissue necrosis, perforation caused by radiotherapy and chemotherapy in patients with lung cancer, and adult respiratory distress syndrome, malnutrition, Hypoproteinemia, diabetes and the application of steroid drugs, etc., due to t...

AI Technical Summary

Problems solved by technology

[0003] At present, the treatment options for BPF include surgery, endoscopic treatment, and conservative medical treatment. Among them, the closure of the fistula is the key, and surgical treatment is the preferred method of fistula closure. The main methods include direct closure of the stump, vascular pedicle Soft tissue flaps (such as pericardium and pectoralis) cover the bronchial stump, surgical thoracoscopic treatment, and thoracic reconstruction. With the development and popularization of bronchoscopic interventional therapy technology, bronchoscopic occlusion of BPF fistula has gradually been applied in clinic, mainly including two occlusion methods, occlusion agent (such as biological glue, autologous blood, OB glue, etc.) And occluders (such as occluder stents, bronchial plugs, atrial septal occluders, etc.), but these occlusion materials have more or less disadvantages such as poor conformability, high price, slow wound healing, etc., and there is still a lack of unified standards Therefore, in the research on BPF occlusion therapy, the selection of effective occlusion materials to meet the required shape, size, biocompatibility, tissue regeneration and mechanical stability is still a matter of biomaterial research. It is an important challenge to explore suitable occlusion materials for the endoscopic interventional treatment of BPF

Images